Phathom Pharmaceuticals (PHAT) Earnings
Price: $4.11
Market Cap: $286.21M
Market Cap: $286.21M
Revenue (TTM): $55.25M
Net Income: $-334.33M
Net Income: $-334.33M
P/E Ratio: -0.87
EPS (TTM): $-4.71
EPS (TTM): $-4.71
Earnings Dates
Phathom Pharmaceuticals (PHAT) reports its earnings quarterly. Here are the key details:
Next Earnings Date
- Date: May 01, 2025
- Time of Day: Before Market Open
- Estimated EPS: $-1.06
Last Earnings Report
- Date: March 06, 2025
- EPS: $-0.79
- EPS Estimate: $-1.29
Phathom Pharmaceuticals's next earnings report is scheduled for May 01, 2025.
In its last earnings report on March 06, 2025, Phathom Pharmaceuticals reported earnings per share (EPS) of $-0.79, compared to an estimated EPS of $-1.29. The company reported revenue of $29.66M, compared to an estimated revenue of $29.04M.
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q4 | 2024 | 2025-03-06 | $-1.29 | $-0.79 |
| Read Transcript | Q3 | 2024 | 2024-11-10 | N/A | N/A |
| Read Transcript | Q2 | 2024 | 2024-08-10 | N/A | N/A |
| Read Transcript | Q1 | 2024 | 2024-05-09 | $-1.43 | $-1.42 |
| Read Transcript | Q4 | 2023 | 2024-03-07 | $-0.92 | $-0.80 |
Earnings History
| Date | EPS | EPS Estimate | Revenue | Revenue Estimate |
|---|---|---|---|---|
| March 06, 2025 | $-0.79 | $-1.29 | $29.66M | $29.04M |
| November 07, 2024 | $-1.32 | $-1.57 | $16.35M | $25.77M |
| August 08, 2024 | $-1.25 | $-1.20 | $7.32M | $5.81M |
| May 09, 2024 | $-1.42 | $-1.43 | $1.91M | $2.05M |
| March 07, 2024 | $-0.80 | $-0.92 | $682.00K | $410.00K |
| November 09, 2023 | $-0.76 | $-0.95 | $- | $800.00K |
| August 10, 2023 | $-0.84 | $-0.95 | $- | $- |
| May 10, 2023 | $-0.89 | $-1.34 | $- | $- |
| February 28, 2023 | $-1.33 | $-1.50 | $- | $200.00K |
| November 08, 2022 | $-1.32 | $-1.32 | $- | $- |
| August 02, 2022 | $-1.33 | $-1.03 | $- | $- |
| May 10, 2022 | $-1.07 | $-0.97 | $- | $211.00K |
| March 01, 2022 | $-0.95 | $-0.86 | $- | $- |
| November 08, 2021 | $-0.98 | $-0.78 | $- | $- |
| August 10, 2021 | $-1.00 | $-1.07 | $- | $- |
| May 11, 2021 | $-0.96 | $-1.11 | $- | $- |
| March 30, 2021 | $-1.58 | $-0.93 | $- | $- |
Annual Earnings
Annual Revenue
$55.25M
Fiscal Year 2024Annual Net Income
$-334.33M
Fiscal Year 2024Annual EPS
$-5.29
Fiscal Year 2024Quarterly Earnings
Revenue
$29.66M
Quarter Ending December 31, 2024Net Income
$-74.45M
Quarter Ending December 31, 2024EPS
$-1.05
Quarter Ending December 31, 2024Earnings Metrics
Earnings Yield
-65.17%
Year Ending December 31, 2024P/E Ratio
-1.53
Year Ending December 31, 2024Revenue Per Share
$0.87
Year Ending December 31, 2024Earnings Yield (TTM)
-114.50%
Trailing Twelve MonthsP/E Ratio (TTM)
-0.87
Trailing Twelve MonthsRevenue Per Share (TTM)
$0.78
Trailing Twelve MonthsFrequently Asked Questions
Phathom Pharmaceuticals's next earnings date is scheduled for May 01, 2025. The earnings call is expected to take place before market open.
In its last earnings report on March 06, 2025, Phathom Pharmaceuticals reported earnings per share (EPS) of $-0.79, compared to an estimated EPS of $-1.29. The company reported revenue of $29.66M, compared to an estimated revenue of $29.04M.
Phathom Pharmaceuticals's current Price-to-Earnings (P/E) ratio is -1.53. The trailing twelve months (TTM) P/E ratio is -0.87. The P/E ratio is a valuation metric that compares a company's current share price to its earnings per share (EPS). A higher P/E ratio suggests that investors are expecting higher earnings growth in the future compared to companies with a lower P/E ratio.
For the fiscal year ending December 31, 2024, Phathom Pharmaceuticals reported total revenue of $55.25M and net income of $-334.33M. This represents a net profit margin of -6.0509302831.
Phathom Pharmaceuticals's earnings yield is -65.17%. The earnings yield is the inverse of the P/E ratio and represents the percentage of each dollar invested in the stock that was earned by the company.
Phathom Pharmaceuticals's return on equity (ROE) is 131.84%. ROE is a measure of financial performance calculated by dividing net income by shareholders' equity. It measures how effectively management is using a company's assets to create profits.
Phathom Pharmaceuticals's gross profit margin is 85.57%. This indicates that for every dollar of revenue, the company retains $0.86 as gross profit after accounting for the cost of goods sold.